Novartis
Connections
Quotes
This underscores the importance of drug design and development with the patient and disease process in mind.
Including the initial acquisition payment plus potential additional regulatory milestone payments, the deal with Novartis could exceed $550 million
In contrast, Novartis ('AA'/Stable), Sanofi ('AA-'/ Stable), GlaxoSmithKline ('A+'/Stable) and Bayer ('A-'/Stable) have less headroom within their current ratings to pursue debt-financed investmentsMore quotes »
Around the web
-
Upcoming Economic Outlook - Report Highlights Novartis AG (ADR) and Abbott Laboratories
with growth potential -- there remains strong opportunity within careful discretion. Brighton Markets is releasing new coverage on Novartis AG (ADR) for its current position within the healthcare industry. Novartis AG provides healthcare solutions. The Company 9:14 AM from MarketWire Read more »
-
Positive test boosts Sanofi MS drug hopes
around 35 to 40 percent of MS patients prefer to take no medication rather than face unwanted side effects. MS pills Gilenya by Novartis and Biogen Idec Inc's BG-12 are seen dominating a market that JPMorgan analysts predict growing to $14 billion in 2015 5:54 AM from Yahoo! Health Read more »
-
5-Star Stocks Poised to Pop: Novartis
now over 4%. I really don't think a person could go wrong with [Novartis] at this point. But, then I have been wrong before. [Novartis] has strategic partnerships (such as the one with [Zalicus]) that appear to be very promising as well. If you want market-thumping from Motley Fool Read more »
-
COPD Tops Asthma as the Focus Indication for Next Generation Respiratory Therapies at the 2012 American Thoracic Society Conference
COPD in the US and Europe in mid-2012. However, several competitors are riding on their heels, including Boehringer Ingelheim, Novartis, Almirall/Forest, and the up-and-coming Pearl Therapeutics, with strong FDC candidates in their pipelines. "Pearl Therapeutics from Virtual Press Office Read more »
-
Who Will Conquer The Oral Multiple Sclerosis Market?
all invested heavily in developing an oral drug to treat multiple sclerosis. Merck dropped out when it gave up on Cladribine. Novartis is jumping into the market, but has limited experience, while multiple sclerosis stalwarts like Biogen and Teva are getting from Seeking Alpha Read more »
